International meeting "Immunotherapy of cancer: challenges and needs"
- PMID: 17131119
- PMCID: PMC11030648
- DOI: 10.1007/s00262-006-0251-6
International meeting "Immunotherapy of cancer: challenges and needs"
Abstract
The main aims of the international meeting "Immunotherapy of Cancer: Challenges and Needs" were to review the state of the art of cancer immunotherapy and to identify critical issues which deserve special attention for promoting progress of research in this field, with a particular focus on the perspectives of clinical research. Novel concepts and strategies for identifying, monitoring and predicting effective responses to cancer immunotherapy protocols were presented, focused on the use of adjuvants (CpG oligonucleotides) or cytokines (IFN-alpha) to enhance the efficacy of cancer vaccines. Moreover, the possible advantages of using different types of dendritic cells (for active immunization strategies) or T cells (for adoptive immunotherapy protocols) were debated. A consensus was achieved on the need for enhancing the efficacy of cancer vaccines or adoptive cell immunotherapy by combining these strategies with other anti-cancer treatments, including chemotherapy. Finally, initiatives for promoting clinical research by establishing a strategic cooperation in the field of cancer immunotherapy based on the active participation of all the relevant actors, including public institutions responsible of Public Health, National Cancer Institutes, industry, representatives of regulatory bodies, and patients' organizations were proposed.
Similar articles
-
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?Cancer Res. 2004 Sep 15;64(18):6827-30. doi: 10.1158/0008-5472.CAN-04-2048. Cancer Res. 2004. PMID: 15375003
-
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.Ann N Y Acad Sci. 2010 Apr;1194:169-78. doi: 10.1111/j.1749-6632.2010.05464.x. Ann N Y Acad Sci. 2010. PMID: 20536466 Review.
-
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y. J Transl Med. 2016. PMID: 27846884 Free PMC article.
-
Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines.Stem Cells. 2003;21(4):495-505. doi: 10.1634/stemcells.21-4-495. Stem Cells. 2003. PMID: 12832702
-
Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment.Clin Transl Oncol. 2020 Nov;22(11):1923-1937. doi: 10.1007/s12094-020-02344-4. Epub 2020 Apr 7. Clin Transl Oncol. 2020. PMID: 32266674 Review.
Cited by
-
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.Breast Cancer Res. 2016 Feb 20;18(1):25. doi: 10.1186/s13058-016-0683-7. Breast Cancer Res. 2016. PMID: 26897526 Free PMC article.
References
-
- Speiser DE, Baumgaertner P, Barbey C, et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol. 2006;177:1338–1348. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources